Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Ferrero

Showing results (421-430 of 481) with videos related to

Pageof 49
Sort By:
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Scientific Reports|July 23, 2024
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trialMichele Clerico, Simone Ferrero, Beatrice Alessandria, et al.
Hemasphere|September 13, 2021
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD NetworkBarbara Mantoan, Elisa Genuardi, Martina Ferrante, et al.
The Lancet. Haematology|December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Annalisa Chiappella, Luca Nassi, et al.
Blood|June 23, 2022
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphomaSimone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 23, 2021
Factors predicting morbidity in surgically-staged high-risk endometrial cancer patientsGiorgio Bogani, Andrea Papadia, Alessandro Buda, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
British Journal of Haematology|March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre studyNicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Pageof 49

Showing results (421-430 of 481) with videos related to

Sort By:
Pageof 49
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Scientific Reports|July 23, 2024
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trialMichele Clerico, Simone Ferrero, Beatrice Alessandria, et al.
Hemasphere|September 13, 2021
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD NetworkBarbara Mantoan, Elisa Genuardi, Martina Ferrante, et al.
The Lancet. Haematology|December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Annalisa Chiappella, Luca Nassi, et al.
Blood|June 23, 2022
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphomaSimone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 23, 2021
Factors predicting morbidity in surgically-staged high-risk endometrial cancer patientsGiorgio Bogani, Andrea Papadia, Alessandro Buda, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
British Journal of Haematology|March 9, 2026
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre studyNicolò Danesin, Francesco Autore, Anna Maria Frustaci, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Pageof 49